Alvotech and Cipla Medpro, a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited, have entered into an exclusive partnership to bring key biosimilars to patients in emerging markets such as South Africa.

Alvotech and Cipla partner to ensure access to biosimilars in South Africa

Alvotech announced today that its parent company, Alvotech Holdings SA, has successfully completed a $65 million private placement round.

Alvotech announces private placement financing

Alvotech and DKSH, a leading healthcare provider across 36 emerging countries in South-East Asia, today announced an expansion of their strategic partnership to commercialize six new biosimilar product candidates for the Asian markets.

Alvotech and DKSH extend partnership in Asia

Alvotech and Teva announce strategic partnership to collaborate in the U.S. biosimilar market

Tanya Zharov joins Alvotech as Deputy CEO

Alvotech announces positive top-line results for two comparative studies.

Alvotech and Alvogen launch new B2B business brand

Alvotech and DKSH partner to bring key biosimilar to Asia

Delivering on our promise during the Coronavirus Pandemic

Alvotech and JAMP Pharma enter into an exclusive partnership

Alvotech at CPhI 2019

Peter Goldschmidt, Róbert Wessman, Mark Levick

Alvotech and Stada agree on strategic biosimilar partnership

Yas Holding invests in Alvotech and agrees on a strategic partnership for biosimilar candidates

Alvotech has appointed Joseph Edward McClellan as its new Chief Scientific Officer. McClellan will be leading the company’s R&D functions, with overall responsibility for bringing products to market through its pipeline and overseeing R&D operations across Alvotech’s sites in Reykjavik, Julich, Hanover and Zurich.

Alvotech appoints new Chief Scientific Officer

This promises to be a busy and exciting fall for Alvotech. Once more it will be participating in the world's largest pharmaceutical fair, CPhI, which this year is being hosted in Frankfurt, Germany, from 5-7 November 2019.

Alvotech is warming up for CPhI 2019 in Frankfurt

Alvotech and Prestige Biopharma, today announced a new contract manufacturing partnership for one of Prestige Biopharma´s biosimilar candidates.

Alvotech and Prestige Biopharma announce new manufacturing partnership

Alvotech and Cipla Gulf FZ LLC (“Cipla Gulf”), a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited (BSE: 500087; NSE: CIPLA EQ; hereafter referred to as "Cipla"), today announced that Alvotech and Cipla Gulf have entered into an exclusive partnership for the commercialization of AVT02, an adalimumab biosimilar, in select emerging markets.

Company news

Alvotech and Cipla partner to ensure access to biosimilars in South Africa

Alvotech announces private placement financing

Alvotech and DKSH extend partnership in Asia

Alvotech and Teva announce strategic partnership to collaborate in the U.S. biosimilar market

Tanya Zharov joins Alvotech as Deputy CEO

Alvotech announces positive top-line results for two comparative studies.

Alvotech and Alvogen launch new B2B business brand

Alvotech and DKSH partner to bring key biosimilar to Asia

Delivering on our promise during the Coronavirus Pandemic

Alvotech and JAMP Pharma enter into an exclusive partnership

Alvotech at CPhI 2019

Alvotech and Stada agree on strategic biosimilar partnership

Yas Holding invests in Alvotech and agrees on a strategic partnership for biosimilar candidates

Alvotech appoints new Chief Scientific Officer

Alvotech is warming up for CPhI 2019 in Frankfurt

Alvotech and Prestige Biopharma announce new manufacturing partnership

Alvotech and Cipla gulf into a partnership

Alvotech completes enrollment of phase III study involving biosimilar version of Humira®

Alvotech and Abdi Ibrahim enter into an exclusive partnership

Mark Levick appointed CEO of Alvotech

Alvotech and Fuji Pharma announce agreement

Media Contact

Download center for company logos and images

Sign up for news alerts